CA2065210A1 - Matrice a liberation controlee pour produits pharmaceutiques - Google Patents

Matrice a liberation controlee pour produits pharmaceutiques

Info

Publication number
CA2065210A1
CA2065210A1 CA2065210A CA2065210A CA2065210A1 CA 2065210 A1 CA2065210 A1 CA 2065210A1 CA 2065210 A CA2065210 A CA 2065210A CA 2065210 A CA2065210 A CA 2065210A CA 2065210 A1 CA2065210 A1 CA 2065210A1
Authority
CA
Canada
Prior art keywords
controlled release
pharmaceuticals
matrix
release matrix
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2065210A
Other languages
English (en)
Other versions
CA2065210C (fr
Inventor
Thinnayam N. Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Thinnayam N. Krishnamurthy
Euroceltique, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US758,883 priority Critical
Priority to US07/758,883 priority patent/US5215758A/en
Application filed by Thinnayam N. Krishnamurthy, Euroceltique, S.A. filed Critical Thinnayam N. Krishnamurthy
Publication of CA2065210A1 publication Critical patent/CA2065210A1/fr
Application granted granted Critical
Publication of CA2065210C publication Critical patent/CA2065210C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/964—Sustained or differential release type
    • Y10S514/965—Discrete particles in supporting matrix
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/966—Rectal
CA002065210A 1991-09-11 1992-04-06 Matrice a liberation controlee pour produits pharmaceutiques Expired - Lifetime CA2065210C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US758,883 1991-09-11
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals

Publications (2)

Publication Number Publication Date
CA2065210A1 true CA2065210A1 (fr) 1993-03-12
CA2065210C CA2065210C (fr) 2000-08-29

Family

ID=25053475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065210A Expired - Lifetime CA2065210C (fr) 1991-09-11 1992-04-06 Matrice a liberation controlee pour produits pharmaceutiques

Country Status (13)

Country Link
US (2) US5215758A (fr)
EP (2) EP0698389B1 (fr)
JP (2) JP3034125B2 (fr)
KR (2) KR100203339B1 (fr)
AT (2) AT187887T (fr)
AU (1) AU653048B2 (fr)
CA (1) CA2065210C (fr)
DE (2) DE69230475T2 (fr)
DK (2) DK0531611T3 (fr)
ES (2) ES2139798T3 (fr)
GR (1) GR3022572T3 (fr)
IL (2) IL101758A (fr)
ZA (1) ZA923417B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
EP0652745A1 (fr) * 1992-07-31 1995-05-17 Daratech Pty. Ltd. Implants a liberation regulee
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
KR970064596A (ko) * 1996-03-21 1997-10-13 이우용 직장투여용 치질치료제 조성물
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
DE69739165D1 (de) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CZ299283B6 (cs) * 1997-12-22 2008-06-04 Euro-Celtique, S. A. Léková forma pro perorální podání
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
JP2002525311A (ja) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
ES2304980T3 (es) * 1999-09-30 2008-11-01 Penwest Pharmaceuticals Co. Sistemas de matriz de liberacion sostenida para farmacos altamente solubles.
AT405264T (de) 2000-02-08 2008-09-15 Euro Celtique Sa Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
EP3130338A1 (fr) 2000-02-08 2017-02-15 Euro-Celtique S.A. Formules agonistes opioïdes orales inviolables
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
ES2523145T3 (es) * 2001-05-02 2014-11-21 Euro-Celtique S.A. Formulaciones de oxicodona para ser administradas una vez al día
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
CA2452871C (fr) * 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Compositions a liberation controlee d'oxymorphone
MXPA04000584A (es) * 2001-07-18 2004-04-20 Euro Celtique Sa COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA.
CA2457361C (fr) 2001-08-06 2008-11-04 Christopher Breder Formulations d'agoniste opioide a antagoniste liberable et sequestre
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Formulations d'antagoniste sequestre
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
AU2003224040B2 (en) 2002-04-05 2006-06-22 Mundipharma Pty Limited Pharmaceutical preparation containing oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
JP4808405B2 (ja) * 2002-11-26 2011-11-02 ホ−レンベック ギャリ− ア−ル 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2005020933A2 (fr) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticules pour apport de medicament
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
PT1663229E (pt) 2003-09-25 2010-07-13 Euro Celtique Sa Combinaãžes farmac—uticas de hidrocodona e naltrexona
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (ko) 2005-09-30 2007-06-19 한국콜마 주식회사 패치형태의 리프팅용 2제형 화장료 조성물과 이의 제조방법및 사용방법
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
WO2007077551A2 (fr) * 2005-12-30 2007-07-12 Mor Research Applications Ltd. Dispositif et procédé de traitement du sphincter anal
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
CA2671197A1 (fr) * 2006-07-21 2008-01-24 Lab International Srl Systeme de delivrance hydrophobe empechant les utilisations abusives
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
US8372425B2 (en) * 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AR075735A1 (es) 2009-03-10 2011-04-20 Euro Celtique Sa Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
WO2010146591A2 (fr) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Méthodes et dispositifs pour l'administration d'agents pharmaceutiques dans des orifices du corps
US20130190299A1 (en) 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
NZ612996A (en) 2010-12-23 2015-05-29 Purdue Pharma Lp Tamper resistant solid oral dosage forms
NZ628695A (en) 2012-07-16 2016-02-26 Rhodes Technologies Process for improved opioid synthesis
MX363610B (es) 2012-07-16 2019-03-28 Rhodes Tech Proceso de sintesis de opioides mejorado.
CN102823585B (zh) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 一种水溶性农药缓控释制剂及其制备方法
EP2953618B1 (fr) 2013-02-05 2020-11-11 Purdue Pharma L.P. Formulations pharmaceutiques inviolables
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2970320B1 (fr) 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Solvate méthanolique de sulfate de morphine, son processus de fabrication et ses compositions et procédés associés destinés au traitement de la douleur
WO2015011189A1 (fr) 2013-07-23 2015-01-29 Euro-Celtique S.A. Combinaison d'oxycodone et de naloxone pour utilisation dans le traitement de la douleur chez des patients souffrant de douleur et d'une maladie entraînant une dysbiose intestinale et/ou l'augmentation du risque de translocation bactérienne intestinale
WO2015015146A1 (fr) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Procédé de préparation d'oxymorphone
US20170000727A1 (en) * 2013-12-20 2017-01-05 Disphar International B.V. Dry enema product
CA2937006C (fr) 2014-01-15 2018-12-04 Rhodes Technologies Procede pour une meilleure synthese de l'oxycodone
US9938285B2 (en) 2014-01-15 2018-04-10 Rhodes Technologies Process for improved oxymorphone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (ja) * 1987-12-21 1994-10-26 花王株式会社 多層坐剤
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Also Published As

Publication number Publication date
ES2139798T3 (es) 2000-02-16
DK0531611T3 (da) 1997-05-26
EP0531611B1 (fr) 1996-12-04
US5508043A (en) 1996-04-16
JP3624123B2 (ja) 2005-03-02
KR100225493B1 (en) 1999-10-15
CA2065210C (fr) 2000-08-29
KR930005616A (ko) 1993-04-20
JP2000136149A (ja) 2000-05-16
IL101758D0 (en) 1992-12-30
EP0698389B1 (fr) 1999-12-22
IL117356A (en) 2000-08-31
IL101758A (en) 1996-12-05
ES2097826T3 (es) 1997-04-16
AT187887T (de) 2000-01-15
AT145820T (de) 1996-12-15
DE69215612T2 (de) 1997-05-15
JP3034125B2 (ja) 2000-04-17
DE69230475T2 (de) 2000-07-13
KR100203339B1 (ko) 1999-06-15
EP0698389A1 (fr) 1996-02-28
AU653048B2 (en) 1994-09-15
EP0531611A1 (fr) 1993-03-17
DK0698389T3 (da) 2000-05-01
DE69230475D1 (de) 2000-01-27
GR3022572T3 (en) 1997-05-31
IL117356D0 (en) 1996-07-23
US5215758A (en) 1993-06-01
AU2107392A (en) 1993-03-18
ZA923417B (en) 1993-01-27
JPH05148159A (ja) 1993-06-15
DE69215612D1 (de) 1997-01-16

Similar Documents

Publication Publication Date Title
CA2065210A1 (fr) Matrice a liberation controlee pour produits pharmaceutiques
CA2136411A1 (fr) Comprimes a liberation immediate de medicaments insolubles a revetement pour liberation continue
AU7171191A (en) Preparation of pharmaceutical and other matrix systems by solid-state dissolution
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
AU3326289A (en) Matrix for release of active ingredients
CA2081068A1 (fr) Derives antiviraux de 2-desoxy-2,3-deshydro a substituant en 4 de l'acide .alpha.-d-neuraminique
AU4999890A (en) Pharmaceutical composition providing the sustained release of valproic acid
LU91832I2 (fr) Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®)
CA2116120A1 (fr) Peptides presentant une activite de liberation de l'hormone de croissance
GB1520197A (en) Stable antibiotic compositions
CA2002363A1 (fr) Preparations a liberation continue
CA2068790A1 (fr) Composes antiviraux
CA2302585A1 (fr) Formulations a liberation prolongee
CA2194885A1 (fr) Benzamidines substituees, leur preparation et leur utilisation comme medicaments
NZ337418A (en) Paracetamol composition with improved rate of absorption
IE892285L (en) Use of polymeric compounds in treatment
CA2113916A1 (fr) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide a action analgesique et anti-inflammatoire
SE8800025L (sv) Bioadhesiva farmaceutiska suppositoriepreparat
ES2014518A6 (es) Procedimiento para la produccion de una composicion farmaceutica de liberacion retardada.
JPH04295428A (en) Antiallergic agent
CA2015632A1 (fr) Solutions stables d'un analogue de la rebeccamycine et preparations realisees a partir d'elles
SE8704240D0 (sv) Analgesic preparations
CA2039099A1 (fr) Remplacement de l'argile et du mica par du cmc dans les pates a joints
CA2070366A1 (fr) Composition prophylactique ou therapeutique contre la pleuropneumonie chez les porcs
CA2182812A1 (fr) Composition pharmaceutique pour administration transdermique systemique contenant du morphine-6-glucoronide comme principe actif

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry